Search research articles
Contact Us
Filters
Showing results (71-80 of 87) with videos related to
Page
of 9
Sort By:
American Journal of Hematology
|
January 28, 2023
Quality of life and symptoms among patients with relapsed/refractory AL amyloidosis treated with ixazomib-dexamethasone versus physician's choice
Vaishali Sanchorawala, Ashutosh D Wechalekar, Kihyun Kim, et al.
Blood
|
September 10, 2014
Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis
Donna E Reece, Ute Hegenbart, Vaishali Sanchorawala, et al.
JACC. Cardiooncology
|
November 29, 2022
Outcomes by Cardiac Stage in Patients With Newly Diagnosed AL Amyloidosis: Phase 3 ANDROMEDA Trial
Monique C Minnema, Angela Dispenzieri, Giampaolo Merlini, et al.
Haematologica
|
May 27, 2014
Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naïve patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III)
Arnaud Jaccard, Raymond L Comenzo, Parameswaran Hari, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
August 15, 2018
Outcome of Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis Associated With Deletion of 17p
Sandy W Wong, Ute Hegenbart, Giovanni Palladini, et al.
Journal of Clinical Medicine
|
June 26, 2025
Screening for Systemic Light-Chain Amyloidosis in Patients Over 60 with λ Monoclonal Gammopathies
Ping Zhou, Mahesh M Mansukhani, Raymond Yeh, et al.
Blood
|
June 27, 2023
Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial
Morie A Gertz, Adam D Cohen, Raymond L Comenzo, et al.
Blood
|
April 4, 2020
Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA
Giovanni Palladini, Efstathios Kastritis, Mathew S Maurer, et al.
Annals of Hematology
|
March 2, 2023
Daratumumab plus bortezomib, cyclophosphamide, and dexamethasone in Asian patients with newly diagnosed AL amyloidosis: subgroup analysis of ANDROMEDA
Kenshi Suzuki, Ashutosh D Wechalekar, Kihyun Kim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 20, 2010
Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group
Meletios A Dimopoulos, Evangelos Terpos, Asher Chanan-Khan, et al.
Page
of 9
Search research articles
Search
Showing results (71-80 of 87) with videos related to
Sort By:
Page
of 9
American Journal of Hematology
|
January 28, 2023
Quality of life and symptoms among patients with relapsed/refractory AL amyloidosis treated with ixazomib-dexamethasone versus physician's choice
Vaishali Sanchorawala, Ashutosh D Wechalekar, Kihyun Kim, et al.
Blood
|
September 10, 2014
Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis
Donna E Reece, Ute Hegenbart, Vaishali Sanchorawala, et al.
JACC. Cardiooncology
|
November 29, 2022
Outcomes by Cardiac Stage in Patients With Newly Diagnosed AL Amyloidosis: Phase 3 ANDROMEDA Trial
Monique C Minnema, Angela Dispenzieri, Giampaolo Merlini, et al.
Haematologica
|
May 27, 2014
Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naïve patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III)
Arnaud Jaccard, Raymond L Comenzo, Parameswaran Hari, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
August 15, 2018
Outcome of Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis Associated With Deletion of 17p
Sandy W Wong, Ute Hegenbart, Giovanni Palladini, et al.
Journal of Clinical Medicine
|
June 26, 2025
Screening for Systemic Light-Chain Amyloidosis in Patients Over 60 with λ Monoclonal Gammopathies
Ping Zhou, Mahesh M Mansukhani, Raymond Yeh, et al.
Blood
|
June 27, 2023
Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial
Morie A Gertz, Adam D Cohen, Raymond L Comenzo, et al.
Blood
|
April 4, 2020
Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA
Giovanni Palladini, Efstathios Kastritis, Mathew S Maurer, et al.
Annals of Hematology
|
March 2, 2023
Daratumumab plus bortezomib, cyclophosphamide, and dexamethasone in Asian patients with newly diagnosed AL amyloidosis: subgroup analysis of ANDROMEDA
Kenshi Suzuki, Ashutosh D Wechalekar, Kihyun Kim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 20, 2010
Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group
Meletios A Dimopoulos, Evangelos Terpos, Asher Chanan-Khan, et al.
Page
of 9